Antiemetic-program with fosaprepitant injection provides similar protection against CINV as oral EMEND Merck announced today results from a fresh non-inferiority trial of an antiemetic regimen containing fosaprepitant dimeglumine administered seeing that an individual intravenous 150-mg dose in combination with a 5-HT3 antagonist and dexamethasone weighed against a three-day regimen of aprepitant with a 5-HT3 antagonist and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in patients receiving a first routine of cisplatin-based chemotherapy. The regimen comprising 150 mg fosaprepitant dimeglumine was not inferior to the regimen with oral aprepitant http://nizagara100mg.net http://nizagara100mg.net .